Synthesis and Evaluation of 11C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography
Authors:
- James M. KellyJKJames M. Kelly
- Thomas M. JeitnerThomas M. Jeitner
- Nicole N. WaterhouseNicole N. Waterhouse
- Wenchao QuWQWenchao Qu
- Ethan J. LinstadELEthan J. Linstad
- Banafshe SamaniBSBanafshe Samani
- Clarence WilliamsCWClarence Williams
- Anastasia NikolopoulouANAnastasia Nikolopoulou
- Alejandro Amor-CoarasaAAAlejandro Amor-Coarasa
- Stephen G. DiMagnoSDStephen G. DiMagno
- John W. BabichJBJohn W. Babich
Open Access
Abstract
Cancer cells require lipids to fulfill energetic, proliferative, and signaling requirements. Even though these cells can take up exogenous fatty acids, the majority exhibit a dependency on de novo fatty acid synthesis. Fatty acid synthase (FASN) is the rate-limiting enzyme in this process. Expression and activity of FASN is elevated in multiple cancers, where it correlates with disease progression and poor prognosis. These observations have sparked interest in developing methods of detecting FASN expression in vivo. One promising approach is the imaging of radiolabeled molecular probes targeting FASN by positron emission tomography (PET). However, although [11C]acetate uptake by prostate cancer cells correlates with FASN expression, no FASN-specific PET probes currently exist. Our aim was to synthesize and evaluate a series of small molecule triazolones based on GSK2194069, an FASN inhibitor with IC50 = 7.7 ± 4.1 nM, for PET imaging of FASN expression. These triazolones were labeled with carbon-11 in good yield and excellent radiochemical purity, and binding to FASN-positive LNCaP cells was significantly higher than FASN-negative PC3 cells. Despite these promising characteristics, however, these molecules exhibited poor in vivo pharmacokinetics and were predominantly retained in lymph nodes and the hepatobiliary system. Future studies will seek to identify structural modifications that improve tumor targeting while maintaining the excretion profile of these first-generation 11C-methyltriazolones.Keywords
Funding Information
- National Cancer Institute (1R21CA213157)
This publication has 65 references indexed in Scilit:
- Fatty Acid Synthase Is a Key Target in Multiple Essential Tumor Functions of Prostate Cancer: Uptake of Radiolabeled Acetate as a Predictor of the Targeted Therapy OutcomePLOS ONE, 2013
- Different fatty acid metabolism effects of (−)-Epigallocatechin-3-Gallate and C75 in Adenocarcinoma lung cancerBMC Cancer, 2012
- A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell linesBreast Cancer Research, 2011
- Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate CancerClinical Cancer Research, 2010
- Fatty Acid Synthase As a Potential Therapeutic Target in CancerFuture Oncology, 2010
- De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapyBritish Journal of Cancer, 2009
- FDG PET in Prostate CancerPET Clinics, 2009
- PET Imaging of Prostate Cancer Using 11C-AcetatePET Clinics, 2009
- PI3K pathway alterations in cancer: variations on a themeOncogene, 2008
- The pathogenesis of prostate cancer: from molecular to metabolic alterationsDiagnostic Histopathology, 2008